(Q46102742)

19 December 2017

meta-analysis

0 references

title

Differential effects of venlafaxine in the treatment of major depressive disorder according to baseline severity (English)

1 reference

19 December 2017

major depressive disorder

main subject

1 reference

6

1 reference

19 December 2017

Hans-Jürgen Möller

4

object named as

Hans-Jürgen Moeller

1 reference

19 December 2017

author name string

Andreas B Schmitt

1

1 reference

19 December 2017

Michael Bauer

2

1 reference

19 December 2017

Hans-Peter Volz

3

1 reference

19 December 2017

Qin Jiang

5

1 reference

19 December 2017

Peter-Andreas Loeschmann

7

1 reference

19 December 2017

publication date

3 March 2009

1 reference

19 December 2017

European Archives of Psychiatry and Clinical Neuroscience

published in

1 reference

19 December 2017

volume

259

1 reference

19 December 2017

issue

6

1 reference

19 December 2017

page(s)

329-339

1 reference

19 December 2017

https://scigraph.springernature.com/pub.10.1007/s00406-009-0003-7

exact match

0 references

cites work

The number needed to treat: a clinically useful measure of treatment effect

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00406-009-0003-7

Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00406-009-0003-7

Numbers needed to treat derived from meta-analyses--sometimes informative, usually misleading

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00406-009-0003-7

Prevalence of risk factors for suicide in patients prescribed venlafaxine, fluoxetine, and citalopram

21 January 2018

1 reference

12 December 2020

The efficacy and tolerability of venlafaxine and paroxetine in outpatients with depressive disorder or dysthymia

1 reference

12 December 2020

Efficacy of antidepressants in the treatment of severe depression: the place of mirtazapine

1 reference

12 December 2020

Increased remission rates with venlafaxine compared with fluoxetine in hospitalized patients with major depression and melancholia

1 reference

12 December 2020

Randomized, double-blind comparison of venlafaxine and fluoxetine in outpatients with major depression.

1 reference

12 December 2020

Re-evaluation of the efficacy and tolerability of venlafaxine vs SSRI: meta-analysis.

1 reference

12 December 2020

A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients

1 reference

12 December 2020

Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression.

1 reference

12 December 2020

Venlafaxine and paroxetine in treatment-resistant depression. Double-blind, randomised comparison.

1 reference

12 December 2020

Efficacy and tolerability of controlled-release paroxetine in the treatment of severe depression: post hoc analysis of pooled data from a subset of subjects in four double-blind clinical trials

1 reference

12 December 2020

Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. Danish University Antidepressant Group

1 reference

12 December 2020

A double-blind, placebo-controlled comparison of venlafaxine and fluoxetine treatment in depressed outpatients

1 reference

12 December 2020

Dosage Finding and Outcome of Venlafaxine Treatment in Psychiatric Outpatients and Inpatients: Results of a Drug Utilization Observation Study

1 reference

12 December 2020

Are all antidepressants the same?

1 reference

12 December 2020

Treatment and secondary prevention of stroke: evidence, costs, and effects on individuals and populations.

1 reference

12 December 2020

A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression

1 reference

12 December 2020

Moclobemide and tricyclic antidepressants in severe depression: meta-analysis and prospective studies

1 reference

12 December 2020

Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis

1 reference

12 December 2020

Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor

1 reference

12 December 2020

Venlafaxine compared with fluoxetine in outpatients with depression and concomitant anxiety

1 reference

12 December 2020

The antidepressant efficacy of reboxetine in patients with severe depression

1 reference

12 December 2020

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders in Primary Care

1 reference

12 December 2020

Dual serotonin and noradrenaline reuptake inhibitors: Focus on their differences.

1 reference

12 December 2020

A double-blind, placebo-controlled study of venlafaxine and fluoxetine in geriatric outpatients with major depression

1 reference

12 December 2020

Treatment with venlafaxine extended release after SSRI nonresponse or intolerance: a randomized comparison of standard- and higher-dosing strategies

1 reference

12 December 2020

Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. Venlafaxine XR 360 Study Group

1 reference

12 December 2020

Randomized, double-blind comparison of venlafaxine and sertraline in outpatients with major depressive disorder. Venlafaxine 631 Study Group

1 reference

12 December 2020

Comprehensive analysis of remission (COMPARE) with venlafaxine versus SSRIs

1 reference

12 December 2020

A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. The Venlafaxine French Inpatient Study Group

1 reference

12 December 2020

The effect of venlafaxine compared with other antidepressants and placebo in the treatment of major depression: a meta-analysis

1 reference

12 December 2020

Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration

1 reference

12 December 2020

Is severe depression a separate indication? ECNP Consensus Meeting September 20, 1996, Amsterdam. European College of Neuropsychopharmacology

1 reference

12 December 2020

A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder.

1 reference

12 December 2020

Comparison of the effects of mirtazapine and fluoxetine in severely depressed patients

1 reference

12 December 2020

Dose response relationship of citalopram 20 mg, citalopram 40 mg and placebo in the treatment of moderate and severe depression

1 reference

12 December 2020

Are all antidepressants really the same? The case of fluoxetine: a systematic review.

1 reference

12 December 2020

Venlafaxine extended release versus conventional antidepressants in the remission of depressive disorders after previous antidepressant failure: ARGOS study

1 reference

12 December 2020

Treatment of SSRI-resistant depression: a meta-analysis comparing within- versus across-class switches

1 reference

12 December 2020

Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology guidelines. British Association for Psychopharmacology

1 reference

12 December 2020

Patterns of depressive symptom response in duloxetine-treated outpatients with mild, moderate or more severe depression

1 reference

12 December 2020

10.1007/S00406-009-0003-7

Identifiers

DOI

1 reference

19 December 2017

1 reference

19 December 2017